Wall Street brokerages expect ADMA Biologics Inc (NASDAQ:ADMA) to announce earnings of ($0.31) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for ADMA Biologics’ earnings, with estimates ranging from ($0.32) to ($0.29). ADMA Biologics reported earnings per share of $0.59 during the same quarter last year, which would suggest a negative year-over-year growth rate of 152.5%. The business is scheduled to issue its next earnings report on Friday, November 2nd.

On average, analysts expect that ADMA Biologics will report full year earnings of ($1.31) per share for the current year, with EPS estimates ranging from ($1.43) to ($1.26). For the next year, analysts anticipate that the company will report earnings of ($0.53) per share, with EPS estimates ranging from ($0.93) to $0.00. Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for ADMA Biologics.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Friday, August 10th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). ADMA Biologics had a negative net margin of 119.34% and a negative return on equity of 89.78%. The business had revenue of $4.66 million for the quarter, compared to the consensus estimate of $5.35 million.

Several research analysts have recently weighed in on the stock. Maxim Group reaffirmed a “buy” rating and issued a $12.00 price target on shares of ADMA Biologics in a report on Wednesday, September 5th. BidaskClub raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a report on Wednesday, September 5th. ValuEngine raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a report on Thursday, July 26th. Chardan Capital assumed coverage on shares of ADMA Biologics in a report on Monday, July 30th. They issued a “buy” rating and a $10.00 price target on the stock. Finally, Oppenheimer assumed coverage on shares of ADMA Biologics in a report on Thursday, July 12th. They issued a “buy” rating and a $13.00 price target on the stock. Seven research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and a consensus price target of $9.50.

ADMA stock traded down $0.18 during midday trading on Friday, reaching $6.24. 3,350 shares of the company’s stock traded hands, compared to its average volume of 180,119. The stock has a market capitalization of $291.54 million, a price-to-earnings ratio of -3.35 and a beta of 2.35. ADMA Biologics has a 52 week low of $2.01 and a 52 week high of $6.96. The company has a debt-to-equity ratio of 0.79, a current ratio of 10.65 and a quick ratio of 8.88.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ADMA. Millennium Management LLC increased its stake in ADMA Biologics by 254.0% in the fourth quarter. Millennium Management LLC now owns 67,533 shares of the biotechnology company’s stock valued at $217,000 after acquiring an additional 48,455 shares during the last quarter. BlackRock Inc. increased its stake in ADMA Biologics by 59.5% in the first quarter. BlackRock Inc. now owns 40,536 shares of the biotechnology company’s stock valued at $186,000 after acquiring an additional 15,115 shares during the last quarter. Spark Investment Management LLC bought a new position in ADMA Biologics in the first quarter valued at $102,000. JPMorgan Chase & Co. bought a new position in ADMA Biologics in the first quarter valued at $182,000. Finally, Element Capital Management LLC bought a new position in ADMA Biologics in the first quarter valued at $118,000. 55.08% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

See Also: What is Considered a Good Return on Equity (ROE)?

Get a free copy of the Zacks research report on ADMA Biologics (ADMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.